Clinical pearls for frontline PCPsA 40-year-old man on today’s schedule has a chief complaint of “excruciating headaches.” ...
Experts view a shift from injecting fentanyl to smoking it as a promising development that could cut overdose deaths and reduce needle-related harms.
The FDA granted breakthrough therapy designation to Rybrevant Faspro based on data from the phase 1b/2 OrigAMI-4 study (NCT06385080).
Military service members and veterans frequently experience post-traumatic stress disorder (PTSD), which is linked to a range of psychological challenges and adverse effects. Cognitive-behavioral ...
The agent, first approved in December for biweekly subcutaneous injection for EGFR-mutated NSCLC, showed similar efficacy and safety when administered monthly.
News-Medical.Net on MSN
Short-duration psychedelic therapy shows promise for major depression treatment
By Tarun Sai Lomte A controlled clinical trial suggests a fast-acting psychedelic approach may reduce depressive symptoms, but researchers stress careful interpretation and the need for larger ...
The FDA has approved a new, simplified monthly subcutaneous (SC) dosing schedule for amivantamab and hyaluronidase-lpuj (Rybrevant Faspro; Johnson & Johnson) for the treatment of patients with ...
The agency last December approved subcutaneous Rybrevant on a biweekly dosing schedule across all of its indications.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results